

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-55. (Canceled)

56. (New) An array for diagnosing ulcerative colitis (UC) in a subject comprising:

(a) a nucleic acid probe for determining an expression level of a melanoma growth stimulatory activity (GRO1) gene product or a SLC26A2 gene product in a sample from said subject; and

(b) a substrate to which said nucleic acid probe is bound,
wherein an increase in the expression level of said GRO1 gene product or a decrease in the expression level of said SLC26A2 gene product in said sample relative to the expression level of the same gene product in normal tissue indicates that said subject has UC.

57. (New) The array of claim 56, wherein the expression level of said GRO1 gene product in said sample is increased relative to the expression level of the same gene product in normal tissue by at least a factor of two.

58. (New) The array of claim 56, wherein the expression level of said SLC26A2 gene product in said sample is decreased relative to the expression level of the same gene product in normal tissue by at least a factor of two.

59. (New) The array of claim 56, wherein said sample is a needle biopsy core, a surgical resection sample, a bowel sample, lymph node tissue, or serum.

60. (New) The array of claim 56, wherein said nucleic acid probe is 12-40 nucleotides in length, complementary to said GRO1 gene product, and hybridizes under high stringency conditions to said GRO1 gene product.

61. (New) The array of claim 60, wherein said nucleic acid probe consists of a sequence that is complementary to 12-40 consecutive nucleotides of SEQ ID NO:2.

62. (New) The array of claim 56, wherein said nucleic acid probe is 12-40 nucleotides in length, complementary to said SLC26A2 gene product, and hybridizes under high stringency conditions to said SLC26A2 gene product.

63. (New) The array of claim 62, wherein said nucleic acid probe consists of a sequence that is complementary to 12-40 consecutive nucleotides of SEQ ID NO:176.

64. (New) The array of claim 56, wherein said substrate is selected from the group consisting of paper, a membrane, a filter, a chip, a pin, and glass.

65. (New) The array of claim 56, wherein said nucleic acid probe is bound to said substrate by covalent bonds or hydrophobic interactions.

66. (New) The array of claim 56, wherein said nucleic acid probe is spotted onto said substrate in a two-dimensional matrix or array.

67. (New) The array of claim 56, wherein said nucleic acid probe further comprises a detectable label.

68. (New) The array of claim 67, wherein said detectable label is selected from the group consisting of a radioisotope, a fluorescent compound, a chemiluminescent compound, an enzyme, and an enzyme co-factor.